{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:58:25Z","timestamp":1787237905345,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Deciphera"},{"name":"Blueprint"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Glaxo Smith-Kline"},{"DOI":"10.13039\/501100013119","name":"Pharmamar","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013119","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Pierre Fabre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.dld.2019.07.006","type":"journal-article","created":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T07:31:57Z","timestamp":1564817517000},"page":"1223-1231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)"],"prefix":"10.1016","volume":"51","author":[{"given":"Bruno","family":"Landi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Bonvalot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Brasseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Michel","family":"Coindre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Fran\u00e7ois","family":"Emile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Hautefeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Honore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lartigau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Mantion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pracht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Le Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 4","key":"10.1016\/j.dld.2019.07.006_bib0005","doi-asserted-by":"crossref","first-page":"iv68","DOI":"10.1093\/annonc\/mdy095","article-title":"Gastrointestinal stromal tumours: ESMO-EUROCAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0010","doi-asserted-by":"crossref","first-page":"853","DOI":"10.6004\/jnccn.2014.0080","article-title":"Gastrointestinal stromal tumours, version 2.2014","volume":"12","author":"Von Mehren","year":"2014","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.dld.2019.07.006_bib0015","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2016.02.021","article-title":"Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour\u2014does it increase the risk for tumour cell seeding and recurrence?","volume":"59","author":"Eriksson","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2019.07.006_bib0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13053-016-0055-4","article-title":"Syndromic gastrointestinal stromal tumours","volume":"14","author":"Ricci","year":"2016","journal-title":"Hered Cancer Clin Pract"},{"key":"10.1016\/j.dld.2019.07.006_bib0025","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.ejca.2013.04.005","article-title":"Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13","volume":"49","author":"Bachet","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2019.07.006_bib0030","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gcb.2009.06.019","article-title":"Gastrointestinal stromal tumours (GIST) <5 cm in size: review of the literature and expert propositions for clinical management","volume":"34","author":"Landi","year":"2010","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.dld.2019.07.006_bib0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12967-017-1212-x","article-title":"The progressive fragmentation of the KIT\/PDGFRA wild-type (WT) gastrointestinal stromal tumours (GIST)","volume":"15","author":"Nannini","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.dld.2019.07.006_bib0040","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/hupa.2002.123545","article-title":"Diagnosis of gastrointestinal stromal tumours: a consensus approach","volume":"33","author":"Fletcher","year":"2002","journal-title":"Hum Pathol"},{"key":"10.1016\/j.dld.2019.07.006_bib0045","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","article-title":"Gastrointestinal stromal tumours: pathology and prognosis at different sites","volume":"23","author":"Miettinen","year":"2006","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.dld.2019.07.006_bib0050","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.humpath.2008.06.025","article-title":"Risk stratification of patients diagnosed with gastrointestinal stromal tumour","volume":"39","author":"Joensuu","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1016\/j.dld.2019.07.006_bib0055","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1470-2045(11)70299-6","article-title":"Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts","volume":"13","author":"Joensuu","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0060","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2014.57.4970","article-title":"KIT and PDGFRA mutations and the risk of GI stromal tumour recurrence","volume":"33","author":"Joensuu","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0065","series-title":"Monographie de l\u2019Association Fran\u00e7aise de chirurgie, Edition Arnette","author":"Brigant","year":"2015"},{"key":"10.1016\/j.dld.2019.07.006_bib0070","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.ejso.2014.04.011","article-title":"Conservative surgery vs. duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors: a retrospective review of 114 patients from the French sarcoma group","volume":"40","author":"Duffaud","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0075","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.ejso.2017.03.017","article-title":"French Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours: a retrospective study of the French Sarcoma Group","volume":"43","author":"Duffaud","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0080","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1245\/s10434-013-3013-7","article-title":"Neoadjuvant imatinib in locally advanced GISTs: the EORTC STBSG experience","volume":"20","author":"Rutkowski","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0085","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib in advanced gastrointestinal stromal tumours","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2019.07.006_bib0090","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2019.07.006_bib0095","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours expressing the kit receptor tyrosine kinase","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0100","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.ejso.2018.06.003","article-title":"Surgical management of metastatic gastrointestinal stromal tumour","volume":"44","author":"Schrage","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0105","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.ejca.2014.03.280","article-title":"Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China","volume":"50","author":"Du","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2019.07.006_bib0110","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2015.62.9170","article-title":"Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: a prospective study","volume":"34","author":"Joensuu","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0115","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2009.24.2099","article-title":"Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumours: a meta-analysis of 1,640 patients","volume":"28","author":"Gastrointestinal Stromal Tumour Meta-Analysis Group","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0120","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1158\/1078-0432.CCR-11-3025","article-title":"Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumours in the tyrosine kinase inhibitor era","volume":"18","author":"Cassier","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2019.07.006_bib0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2217\/fon-2016-0409","article-title":"Key messages from the BFR14 trial of the French Sarcoma Group","volume":"13","author":"Patrikidou","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0130","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumours","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0135","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","article-title":"Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double- blind, placebo-controlled trial","volume":"373","author":"Dematteo","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2019.07.006_bib0140","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.2013.51.2046","article-title":"Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumour: the ACOSOG Z9001 trial","volume":"32","author":"Corless","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0145","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.2012.347","article-title":"One versus three years of adjuvant imatinib for operable gastrointestinal stromal tumour: a randomized trial","volume":"307","author":"Joensuu","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2019.07.006_bib0150","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2015.62.9170","article-title":"Adjuvant imatinib for high-risk GI stromal tumour: analysis of a randomized trial","volume":"34","author":"Joensuu","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0155","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1200\/JCO.2015.62.4304","article-title":"Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumours treated with imatinib as an adjuvant: a EORTC soft tissue and bone sarcoma group intergroup randomized trial","volume":"20","author":"Casali","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.dld.2019.07.006_bib0160","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.4060","article-title":"Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients ith resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial","volume":"4","author":"Raut","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0165","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2019.07.006_bib0170","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumour","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2019.07.006_bib0175","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","article-title":"Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure","volume":"45","author":"George","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2019.07.006_bib0180","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacity and safety of regorafenib for Advanced gastrointestinal stromal tumours after failure of ilatinib and sunitinib. An international, multicentre, randomized, placebo-controlled phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865819306905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865819306905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:09:40Z","timestamp":1761624580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865819306905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1590865819306905"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2019.07.006","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2019.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}